Literature DB >> 28966727

Identification of candidate genes associated with triple negative breast cancer.

Audrey Player1, Nissi Abraham1, Kayla Burrell1, Iria Ondo Bengone1, Anthony Harris1, Lisa Nunez1, Telisa Willaims1, Sharon Kwende1, Wiley Walls1.   

Abstract

When triple negative breast cancer (TNBC) are analyzed by gene expression profiling different subclasses are identified, at least one characterized by genes related to immune signaling mechanisms supporting the role of these genes in the cancers. In an earlier study we observed differences in TNBC cell lines with respect to their expression of the cytokine IL32. Our analyses showed that certain cell lines expressed higher levels of the cytokine compared to others. Because TNBC are heterogeneous and immune-related genes appear to play a pivotal role in these cancers, we chose to examine the transcriptomes of the different cell lines based on IL32 expression. We performed group analyses of TNBC cell lines demonstrating high IL32 compared to low IL32 levels and identified IL32, GATA3, MYBL1, ETS1, PTX3 and TMEM158 as differentially associated with a subpopulation of TNBC. The six candidate genes were validated experimental and in different patient datasets. The genes distinguished a subset of TNBC from other TNBC, and TNBC from normal, luminal A, luminal B, and HER2 patient samples. The current project serves as a preliminary study in which we outline the discovery and validation of our list of six candidate genes.

Entities:  

Keywords:  ETS1; GATA3; IL32; MYBL1; TMEM158

Year:  2017        PMID: 28966727      PMCID: PMC5620011          DOI: 10.18632/genesandcancer.147

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  49 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis.

Authors:  Daniel Iglesias; Antonia M Fernández-Peralta; Nargisse Nejda; Lidia Daimiel; Mariano Moreno Azcoita; Soledad Oliart; Juan J González-Aguilera
Journal:  Cancer Genet Cytogenet       Date:  2006-06

Review 3.  Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.

Authors:  Jodi E Goldberg; Kathryn L Schwertfeger
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

4.  Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Authors:  Virginie Maire; Fariba Némati; Marion Richardson; Anne Vincent-Salomon; Bruno Tesson; Guillem Rigaill; Eléonore Gravier; Bérengère Marty-Prouvost; Leanne De Koning; Guillaume Lang; David Gentien; Aurélie Dumont; Emmanuel Barillot; Elisabetta Marangoni; Didier Decaudin; Sergio Roman-Roman; Alain Pierré; Francisco Cruzalegui; Stéphane Depil; Gordon C Tucker; Thierry Dubois
Journal:  Cancer Res       Date:  2012-11-09       Impact factor: 12.701

5.  Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas.

Authors:  Javier Silva; José M A Silva; Marta Barradas; José M García; Gemma Domínguez; Vanesa García; Cristina Peña; Isabel Gallego; Ruth Espinosa; Manuel Serrano; Félix Bonilla
Journal:  Mutat Res       Date:  2005-11-08       Impact factor: 2.433

6.  The NCI/CIT microArray database (mAdb) system - bioinformatics for the management and analysis of Affymetrix and spotted gene expression microarrays.

Authors:  J M Greene; E Asaki; X Bian; C Bock; S Castillo; G Chandramouli; R Martell; K Meyer; T Ruppert; S Sundaram; J Tomlin; L Yang; J Powell
Journal:  AMIA Annu Symp Proc       Date:  2003

7.  Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

Authors:  Sylvia Adams; Lori J Goldstein; Joseph A Sparano; Sandra Demaria; Sunil S Badve
Journal:  Oncoimmunology       Date:  2015-07-27       Impact factor: 8.110

Review 8.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

9.  Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.

Authors:  Hae Hyun Jung; Soo-Hyeon Lee; Ji-Yeon Kim; Jin Seok Ahn; Yeon Hee Park; Young-Hyuck Im
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

10.  The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.

Authors:  Damian Szklarczyk; John H Morris; Helen Cook; Michael Kuhn; Stefan Wyder; Milan Simonovic; Alberto Santos; Nadezhda T Doncheva; Alexander Roth; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2016-10-18       Impact factor: 16.971

View more
  6 in total

1.  Circulating nuclear factor-kappa B mediates cancer-associated inflammation in human breast and colon cancer.

Authors:  Kundaktepe Berrin Papila; Volkan Sozer; Kocael Pinar Cigdem; Sinem Durmus; Dilara Kurtulus; Cigdem Papila; Remise Gelisgen; Hafize Uzun
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

2.  TMEM158 Regulates the Canonical and Non-Canonical Pathways of TGF-β to Mediate EMT in Triple-Negative Breast Cancer.

Authors:  Jiaci Tong; Haoran Li; Ye Hu; ZuoWei Zhao; Man Li
Journal:  J Cancer       Date:  2022-05-21       Impact factor: 4.478

Review 3.  The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer.

Authors:  Andrea Doni; Matteo Stravalaci; Antonio Inforzato; Elena Magrini; Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

4.  PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.

Authors:  Giuseppe Stefano Netti; Giuseppe Lucarelli; Federica Spadaccino; Giuseppe Castellano; Margherita Gigante; Chiara Divella; Maria Teresa Rocchetti; Federica Rascio; Vito Mancini; Giovanni Stallone; Giuseppe Carrieri; Loreto Gesualdo; Michele Battaglia; Elena Ranieri
Journal:  Aging (Albany NY)       Date:  2020-04-28       Impact factor: 5.682

5.  Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients.

Authors:  Lingchen Wang; Wenhua Wang; Shaopeng Zeng; Huilie Zheng; Quqin Lu
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

6.  MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.

Authors:  Jinrong Zhu; Yongqi Wu; Yijian Yu; Yan Li; Jianfei Shen; Rongxin Zhang
Journal:  Cell Death Dis       Date:  2022-08-20       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.